Inhibition of the glucocorticoid receptor attenuates proteinuric kidney diseases in multiple species.

ABSTRACT:

Background

Glucocorticoids are the treatment of choice for proteinuric patients with minimal change disease (MCD) and primary focal segmental glomerulosclerosis (FSGS). Immunosuppressive as well as direct effects on podocytes are believed to mediate their actions. In this study, we analyzed the anti-proteinuric effects of inhibition of the glucocorticoid receptor (GR) in glomerular epithelial cells, including podocytes.

Methods

We employed genetic and pharmacological approaches to inhibit the GR. Genetically, we used Pax8-Cre/GRfl/fl mice to specifically inactivate the GR in kidney epithelial cells. Pharmacologically, we utilized a glucocorticoid antagonist called mifepristone.

Results

Genetic inactivation of GR, specifically in kidney epithelial cells, using Pax8-Cre

SUBMITTER: Stamellou E 

PROVIDER: S-EPMC11210988 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature